ClinicalTrials.gg
CompletedNCT00521586Updated Apr 9, 2015Results posted

Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

A Phase 3 interventional study of 13 valent pneumococcal conjugate vaccine and 13 valent pneumococcal conjugate vaccine in Influenza, sponsored by Pfizer. Completed at 41 sites in United States. Open to participants aged 50 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-09.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,116
Allocation
Randomized
Ages
50 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Influenza, Human by Pfizer — 1 open to participants now, 2 under way, none of them phase 3. Influenza, Human · Pfizer.

Enrollment
5th of 11
1,116 · median 882
Started
2007
the only one that year
Phase 3
2 of 15
none open now
Registered
1st of 15
by date

Among the 15 studies in Influenza, Human by Pfizer, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2007, is one of 2 in phase 3, and was the 1st registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

1 of the 15 studies in Influenza, Human by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 50 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Influenza, Human by Pfizer, or all of them as a file.
02

Study summary

This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years who are naive to 23-valent pneumococcal polysaccharide vaccine (23vPS), or when the vaccines are given 1 month apart. It will also evaluate the immune response to 13vPnC once per year for 4 years and then to a second dose of 13vPnC given 5 years after the first dose.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • Pneumococcal Conjugate Vaccine
04

Who can participate

Ages eligible
50 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 50 to 59 years
  • Determined by medical history, physical examination and clinical judgement to be eligible for the study
  • Able to complete electronic diary
  • Available for the 5 year 9 month duration of the study

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with any licensed or experimental pneumococcal vaccine
  • Allergic to egg proteins and chicken proteins
  • History of Guillian-Barre syndrome
  • Vaccination with TIV within 6 months before study start
  • Vaccination with diphtheria-containing vaccine within 6 months of study start
  • Serious chronic disorders including immunodeficiency or
  • Known or suspected to any vaccine or vaccine component
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,116 participants (actual)

Study arms

  • Other
    1

    arm 1 = TIV +13vPnC at visit 1, placebo at visit 2 then 13vPnC at year 5

    Biological: 13 valent pneumococcal conjugate vaccine

  • Other
    2

    arm 2 = TIV + placebo at visit 1, then 13vPnC at visit 2 and at year 5

    Biological: 13 valent pneumococcal conjugate vaccine

Interventions

  • TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5

    Also known as: 0.5 mL dose of TIV and 13vPnC at dose 1, 0.5 mL dose of of placebo at dose 2, and 0.5ml dose of 13vPnC at year 5 will be administered into left deltoid muscle

  • TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5

    Also known as: 0.5 mL dose of TIV and of placebo at dose 1 and 0.5 mL dose of 13vPnC at dose 2 and year 5 will be administered into left deltoid muscle

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving at Least 4-fold Increase in Titer for Concomitant Trivalent Inactivated Influenza Vaccine (TIV) Antigens 1 Month After Dose 1

    Percentage of participants achieving at least 4-fold increase in titer for concomitant Trivalent Inactivated Influenza Vaccine (TIV) were measured by standard Hemagglutination Inhibition Assay (HAI) for the A/H1, A/H3, and B vaccine strains.Exact, unconditional, 2-sided, 95% confidence intervals (CI) on the difference in proportions (13vPnC+TIV - Placebo+TIV) was calculated. N(number of participants analyzed)=participants with a determinate antibody titer to the given concomitant vaccine antigen. n=participants who met the prespecified level for the given antigen.

    Time frame: 1 month after Dose 1

  2. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose at year 0 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: 1 month after 13vPnC Dose at year 0

Other outcomes

  1. Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC (Year 5)

    Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 Month After 13vPnC (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: 1 month after 13vPnC (Year 5)

  2. Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) Before 13vPnC (Year 5) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

    Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants with immunogenicity data at both Year 5 endpoints.

    Time frame: before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5)

  3. Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold-Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 5)

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before 13vPnC (Year 5) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. n=participants with valid and determinate assay results for the specified serotype from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

    Time frame: before 13vPnC (Year 5), 1 month after 13vPnC re-vaccinated dose (Year 5)

  4. Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

    Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.n=participants with valid and determinate assay results for the specified serotype for both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

    Time frame: 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)

  5. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to 1 Month After 13vPnC (Year 0)

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

    Time frame: 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)

  6. Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) Before 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

    Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.

    Time frame: before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5)

  7. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 0)

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before13vPnC (Year 0) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

    Time frame: before 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)

  8. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC (Year 0), 1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5)

    Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before, 1 month after 13vPnC (Year 0), at Years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. n=participants with valid and determinate assay results for the specified serotype at before, 1 month after 13vPnC (Year 0), at Years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) blood draws.

    Time frame: Before,1 month after 13vPnC (Year 0), 1, 2, 3, 4 years after initial vaccination (Year 0); before,1 month after 13vPnC (Year 5)

  9. Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC (Year 0),1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5) Relative to Before 13vPnC (Year 0)

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before to 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both the baseline and the various time points.

    Time frame: Before, 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5)

  10. Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) 1 Month After 13vPnC (Year 5)

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 1 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: 1 month after 13vPnC (Year 5)

  11. Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) Before 13vPnC (Year 5) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both Year 5 time points.

    Time frame: before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5)

  12. Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 5)

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before 13vPnC (Year 5) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

    Time frame: before 13vPnC (Year 5), 1 month after 13vPnC re-vaccinated dose (Year 5)

  13. Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) 1 Month After 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points

    Time frame: 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)

  14. Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to 1 Month After 13vPnC (Year 0)

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

    Time frame: 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)

  15. Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) Before 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.

    Time frame: before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5)

  16. Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 0)

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from Before 13vPnC (Year 0) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

    Time frame: Before 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)

  17. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC (Year 0), 1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5)

    Participants received either 0.5 mL dose of 13vPnC intramuscular injection into the deltoid muscle of the left arm along with 0.5-mL TIV intramuscular injection into the deltoid muscle of the right arm at Year 0 on Day 1(Dose1, 13vPnC+TIV), or placebo matched to 13vPnC intramuscular injection into the deltoid muscle of the left arm along with 0.5-mL TIV intramuscular injection into the deltoid muscle of the right arm at Year 0 on Day 1(Dose 1, placebo+TIV). Placebo matched to 13vPnC was administered 1 month after(Dose 2, placebo), or 13vPnC was administered 1 month after (Dose 2, 13vPnC).Participants were further followed-up for 1 month,then attended a 6-month follow-up visit for safety.Participants were then followed-up yearly for 4 years.Participants then received 0.5 mL dose of 13vPnC intramuscular injection into the deltoid muscle of the left arm 5 years after initial vaccination.Participants were further followed-up for 1 month, then attended a 6-month follow-up visit for safety.

    Time frame: Before,1 month after 13vPnC (Year 0), 1, 2, 3, 4 years after initial vaccination (Year 0); before,1 month after 13vPnC (Year 5)

  18. Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC (Year 0),1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5) Relative to Before 13vPnC (Year 0)

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before to 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both the baseline and the various time points.

    Time frame: Before, 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5)

  19. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Dose 1 (Year 0)

    Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder). Local reactions were measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.

    Time frame: Within 14 days after Dose 1 (Year 0)

  20. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Dose 2 (Year 0)

    Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder). Local reactions were measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.

    Time frame: Within 14 days after Dose 2 (Year 0)

  21. Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After 13vPnC (Year 5)

    Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder).

    Time frame: Within 14 days after 13vPnC (Year 5)

  22. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Dose 1 (Year 0)

    Percentage of participants who experienced specific systemic events (mild: 38.0 to 38.4 degrees Celsius \[C\], moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening greater than \[\>\] 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.

    Time frame: Within 14 days after Dose 1 (Year 0)

  23. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Dose 2 (Year 0)

    Percentage of participants who experienced specific systemic events (absent: 38.0 degrees Celsius \[C\], mild: 38.0 to 38.4 degrees C, moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening \> 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.

    Time frame: Within 14 days after Dose 2 (Year 0)

  24. Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After 13vPnC (Year 5)

    Percentage of participants who experienced specific systemic events (Fever: \>= 38.0 degrees Celsius \[C\], mild: 38.0 to 38.4 degrees C, moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening \> 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.

    Time frame: Within 14 days after 13vPnC (Year 5)

  25. Percentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After Dose 1 (Year 0)

    Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity). Acute pain was measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.

    Time frame: Within 30 Minutes After Dose 1 (Year 0)

  26. Percentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After Dose 2 (Year 0)

    Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity). Acute pain was measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.

    Time frame: Within 30 Minutes After Dose 2 (Year 0)

  27. Percentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After 13vPnC (Year 5)

    Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity).

    Time frame: Within 30 Minutes After 13vPnC (Year 5)

  28. Percentage of Participants With Serious Adverse Events (SAEs) or Non-serious Adverse Events (Non-SAEs)

    AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Non-serious AEs are AEs excluding SAEs. In Years 1-4, only deaths and withdrawals due to AEs or SAEs were to be recorded in the case report form.

    Time frame: Signing of informed consent up to 194 days after re-vaccination at Year 5

07

Results

Posted Apr 9, 2015

Participant flow

Initial Vaccination (Year 0)
Participant flow — Initial Vaccination (Year 0)
Milestone13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Started554562
Vaccinated dose 1551560
Vaccinated dose 2538543
Initially reported to complete year 0531529
Completed533533
Not completed2129
Withdrew: Subject request811
Withdrew: Lost to follow-up510
Withdrew: Protocol violation25
Withdrew: Other, unspecified31
Withdrew: Investigator request20
Withdrew: Adverse event01
Withdrew: Death10
Withdrew: Failed to return01
Follow-up (From 6-month[Year 0]-Year 5)
Participant flow — Follow-up (From 6-month[Year 0]-Year 5)
Milestone13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Started533533
Completed364363
Not completed169170
Withdrew: Adverse event51
Withdrew: Death52
Withdrew: Failed to return73
Withdrew: Investigator request33
Withdrew: Lost to follow-up5556
Withdrew: Other2226
Withdrew: Protocol violation1822
Withdrew: Subject request5457
Revaccination With 13vPnC (Year 5)
Participant flow — Revaccination With 13vPnC (Year 5)
Milestone13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Started364363
Vaccinated 13vpnc (year 5)364363
Completed 1 month follow-up363359
Completed 6 month follow-up361351
Completed361351
Not completed312
Withdrew: Subject request01
Withdrew: Failed to return14
Withdrew: Lost to follow-up27

Outcome measures

PrimaryPercentage of Participants Achieving at Least 4-fold Increase in Titer for Concomitant Trivalent Inactivated Influenza Vaccine (TIV) Antigens 1 Month After Dose 1

Percentage of participants achieving at least 4-fold increase in titer for concomitant Trivalent Inactivated Influenza Vaccine (TIV) were measured by standard Hemagglutination Inhibition Assay (HAI) for the A/H1, A/H3, and B vaccine strains.Exact, unconditional, 2-sided, 95% confidence intervals (CI) on the difference in proportions (13vPnC+TIV - Placebo+TIV) was calculated. N(number of participants analyzed)=participants with a determinate antibody titer to the given concomitant vaccine antigen. n=participants who met the prespecified level for the given antigen.

Time frame:
1 month after Dose 1
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least 4-fold Increase in Titer for Concomitant Trivalent Inactivated Influenza Vaccine (TIV) Antigens 1 Month After Dose 1
percentage of participants13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
A/H1N1 strain (n=445,431)84.0 (80.6 to 87.0)81.2 (77.6 to 84.4)
A/H3N2 strain (n=377,369)71.1 (67.1 to 75.0)69.5 (65.4 to 73.4)
B strain (n=321,320)60.6 (56.3 to 64.8)60.3 (56.0 to 64.5)
Statistical analysis
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Percent difference: 2.8 · 95% CI -1.8 to 7.4
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Percent difference: 1.6 · 95% CI -3.9 to 7.2
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Percent difference: 0.3 · 95% CI -5.6 to 6.2
PrimaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose at year 0 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
1 month after 13vPnC Dose at year 0
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose
microgram per milliliter (mcg/mL)13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Serotype 1 (n=292, 289)4.05 (3.41 to 4.81)5.45 (4.57 to 6.49)
Serotype 3 (n=290, 288)1.15 (1.02 to 1.29)1.46 (1.29 to 1.65)
Serotype 4 (n=290, 288)2.35 (2.00 to 2.77)3.41 (2.89 to 4.02)
Serotype 5 (n=293, 289)6.03 (5.16 to 7.05)7.18 (6.13 to 8.40)
Serotype 6A (n=293, 288)5.78 (5.02 to 6.64)6.70 (5.74 to 7.83)
Serotype 6B (n=292, 289)7.58 (6.54 to 8.78)10.09 (8.57 to 11.86)
Serotype 7F (n=293, 289)8.14 (7.07 to 9.38)10.57 (9.11 to 12.27)
Serotype 9V (n=293, 289)4.96 (4.32 to 5.70)6.97 (6.08 to 7.99)
Serotype 14 (n=294, 288)10.77 (9.04 to 12.82)14.05 (11.82 to 16.71)
Serotype 18C (n=293, 288)9.65 (8.32 to 11.19)13.49 (11.62 to 15.67)
Serotype 19A (n=294, 289)16.80 (14.75 to 19.14)18.84 (16.37 to 21.68)
Serotype 19F (n=291, 286)6.13 (5.21 to 7.22)7.13 (5.90 to 8.63)
Serotype 23F (n=294, 289)7.17 (6.06 to 8.49)8.54 (7.11 to 10.25)
Statistical analysis
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.74 · 95% CI 0.58 to 0.95
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.79 · 95% CI 0.66 to 0.93
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.69 · 95% CI 0.55 to 0.87
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.84 · 95% CI 0.67 to 1.05
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.86 · 95% CI 0.70 to 1.06
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.75 · 95% CI 0.60 to 0.93
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.77 · 95% CI 0.63 to 0.95
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.71 · 95% CI 0.59 to 0.86
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.77 · 95% CI 0.60 to 0.98
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.72 · 95% CI 0.58 to 0.88
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.89 · 95% CI 0.74 to 1.08
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.86 · 95% CI 0.67 to 1.10
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.84 · 95% CI 0.66 to 1.08
Other pre-specifiedSerotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC (Year 5)

Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 Month After 13vPnC (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
1 month after 13vPnC (Year 5)
Reported as:
Geometric mean · titers
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) 1 Month After 13vPnC (Year 5)
titers13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Serotype 1 (n=349,352 )178 (150.6 to 210.1)168 (141.4 to 199.9)
Serotype 3(n=355, 352)59 (52.1 to 67.1)66 (57.7 to 75.0)
Serotype 4(n=357,350)1618 (1453.2 to 1801.5)1491 (1318.4 to 1685.8)
Serotype 5(n=350,353)267 (224.7 to 317.0)312 (266.2 to 366.6)
Serotype 6A(n=356,350)4266 (3752.0 to 4849.9)3994 (3442.0 to 4635.6)
Serotype 6B(n=354,351)3583 (3130.7 to 4101.8)3567 (3149.2 to 4040.9)
Serotype 7F(n=355,352)1636 (1459.8 to 1834.3)1803 (1624.6 to 2001.7)
Serotype 9V(n=353,347)1818 (1581.5 to 2090.6)1551 (1282.4 to 1875.8)
Serotype 14(n=355,350)1110 (993.2 to 1239.7)1107 (988.1 to 1240.1)
Serotype 18C(n=353,348)1800 (1571.8 to 2060.7)1738 (1485.4 to 2033.8)
Serotype 19A(n=354,352)913 (815.7 to 1022.9)890 (787.1 to 1006.5)
Serotype 19F(n=345,338)1202 (1030.9 to 1402.0)1140 (976.7 to 1330.3)
Serotype 23F(n=354,350)1837 (1562.6 to 2159.9)1820 (1552.0 to 2134.4)
Statistical analysis
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.1 · 95% CI 0.83 to 1.34
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.9 · 95% CI 0.75 to 1.08
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.1 · 95% CI 0.92 to 1.28
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.9 · 95% CI 0.68 to 1.08
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.1 · 95% CI 0.88 to 1.30
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.0 · 95% CI 0.84 to 1.21
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.9 · 95% CI 0.78 to 1.06
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.2 · 95% CI 0.93 to 1.48
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.0 · 95% CI 0.86 to 1.17
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.0 · 95% CI 0.84 to 1.27
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.0 · 95% CI 0.87 to 1.21
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.1 · 95% CI 0.85 to 1.31
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.0 · 95% CI 0.80 to 1.27
Other pre-specifiedSerotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) Before 13vPnC (Year 5) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants with immunogenicity data at both Year 5 endpoints.

Time frame:
before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · titers
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) Before 13vPnC (Year 5) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
titersAll Participants
Serotype 1:Before 13vPnC (Year 5),(n=690)10 (8.7 to 10.7)
Serotype 1: After 13vPnC (Year 5),(n=690)173 (153.5 to 195.5)
Serotype 3: Before 13vPnC (Year 5),(n=699)8 (7.6 to 9.2)
Serotype 3: After 13vPnC (Year 5),(n=699)62 (56.6 to 68.0)
Serotype 4 : Before 13vPnC (Year 5),(n=667)88 (73.5 to 106.6)
Serotype 4 : After 13vPnC (Year 5),(n=667)1553 (1426.5 to 1691.4)
Serotype 5 : Before 13vPnC (Year 5),(n=694)16 (13.8 to 18.0)
Serotype 5 :After 13vPnC (Year 5),(n=694)290 (257.8 to 326.4)
Serotype 6A : Before 13vPnC (Year 5),(n=677)173 (144.5 to 206.8)
Serotype 6A : After 13vPnC (Year 5),(n=677)4072 (3684.3 to 4500.2)
Serotype 6B : Before 13vPnC (Year 5),(n=650)209 (174.0 to 252.1)
Serotype 6B : After 13vPnC (Year 5),(n=650)3504 (3181.3 to 3859.7)
Serotype 7F: Before 13vPnC (Year 5),(n=687)122 (100.9 to 147.7)
Serotype 7F: After 13vPnC (Year 5),(n=687)1697 (1569.0 to 1834.7)
Serotype 9V: Before 13vPnC (Year 5),(n=671)97 (78.1 to 119.5)
Serotype 9V: After 13vPnC (Year 5),(n=671)1669 (1479.9 to 1882.6)
Serotype 14: Before 13vPnC (Year 5),(n=678)289 (250.5 to 332.9)
Serotype 14: After 13vPnC (Year 5),(n=678)1096 (1011.1 to 1187.9)
Serotype 18C: Before 13vPnC (Year 5),(n=683)120 (100.5 to 143.6)
Serotype 18C: After 13vPnC (Year 5),(n=683)1748 (1573.5 to 1941.9)
Serotype 19A: Before 13vPnC (Year 5),(n=696)113 (99.0 to 127.9)
Serotype 19A: After 13vPnC (Year 5),(n=696)900 (827.1 to 978.4)
Serotype 19F: Before 13vPnC (Year 5),(n=649)38 (31.5 to 45.1)
Serotype 19F: After 13vPnC (Year 5),(n=649)1146 (1024.6 to 1282.9)
Serotype 23F: Before 13vPnC (Year 5),(n=685)50 (42.2 to 59.0)
Serotype 23F: After 13vPnC (Year 5),(n=685)1819 (1620.2 to 2043.0)
Other pre-specifiedSerotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold-Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 5)

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before 13vPnC (Year 5) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. n=participants with valid and determinate assay results for the specified serotype from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

Time frame:
before 13vPnC (Year 5), 1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · fold-rises
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold-Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 5)
fold-risesAll Participants
Serotype 1 (n=690)18.0 (15.72 to 20.53)
Serotype 3(n=699)7.4 (6.70 to 8.19)
Serotype 4(n=667)17.6 (14.59 to 21.12)
Serotype 5 (n=694)18.4 (16.12 to 20.99)
Serotype 6A(n=677)23.6 (19.74 to 28.11)
Serotype 6B(n=650)16.7 (13.98 to 20.02)
Serotype 7F(n=687)13.9 (11.48 to 16.83)
Serotype 9V(n=671)17.3 (14.10 to 21.17)
Serotype 14(n=678)3.8 (3.32 to 4.34)
Serotype 18C(n=683)14.6 (12.27 to 17.25)
Serotype 19A(n=696)8.0 (7.07 to 9.04)
Serotype 19F(n=649)30.4 (25.47 to 36.34)
Serotype 23F(n=685)36.5 (30.84 to 43.12)
Other pre-specifiedSerotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.n=participants with valid and determinate assay results for the specified serotype for both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

Time frame:
1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · titers
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
titersAll Participants
Serotype 1:After 13vPnC (Year 0),(n=381)217 (184.0 to 255.0)
Serotype 1: After 13vPnC (Year 5),(n=381)183 (156.6 to 214.6)
Serotype 3: After 13vPnC (Year 0),(n=374)69 (60.0 to 78.7)
Serotype 3: After 13vPnC (Year 5),(n=374)61 (54.4 to 69.0)
Serotype 4 : After 13vPnC (Year 0),(n=382)1905 (1666.7 to 2177.5)
Serotype 4 : After 13vPnC (Year 5),(n=382)1589 (1426.0 to 1771.3)
Serotype 5 : After 13vPnC (Year 0),(n=374)129 (104.5 to 160.1)
Serotype 5 :After 13vPnC (Year 5),(n=374)300 (256.8 to 350.4)
Serotype 6A : After 13vPnC (Year 0),(n=390)2779 (2345.5 to 3293.0)
Serotype 6A : After 13vPnC (Year 5),(n=390)4196 (3677.1 to 4787.1)
Serotype 6B : After 13vPnC (Year 0),(n=380)3089 (2662.6 to 3584.8)
Serotype 6B : After 13vPnC (Year 5),(n=380)3541 (3158.7 to 3968.9)
Serotype 7F: After 13vPnC (Year 0),(n=372)2196 (1839.7 to 2620.3)
Serotype 7F: After 13vPnC (Year 5),(n=372)1768 (1596.9 to 1958.3)
Serotype 9V: After 13vPnC (Year 0),(n=387)1343 (1097.1 to 1643.7)
Serotype 9V: After 13vPnC (Year 5),(n=387)1768 (1501.6 to 2081.6)
Serotype 14: After 13vPnC (Year 0),(n=383)1169 (994.7 to 1374.1)
Serotype 14: After 13vPnC (Year 5),(n=383)1135 (1017.5 to 1265.1)
Serotype 18C: After 13vPnC (Year 0),(n=381)1728 (1420.9 to 2101.1)
Serotype 18C: After 13vPnC (Year 5),(n=381)1772 (1540.0 to 2038.3)
Serotype 19A: After 13vPnC (Year 0),(n=378)879 (769.0 to 1005.4)
Serotype 19A: After 13vPnC (Year 5),(n=378)858 (763.9 to 963.0)
Serotype 19F: After 13vPnC (Year 0),(n=369)472 (383.9 to 579.9)
Serotype 19F: After 13vPnC (Year 5),(n=369)1139 (982.7 to 1319.6)
Serotype 23F: After 13vPnC (Year 0),(n=368)494 (396.4 to 615.2)
Serotype 23F: After 13vPnC (Year 5),(n=368)1955 (1700.6 to 2246.7)
Other pre-specifiedSerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to 1 Month After 13vPnC (Year 0)

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

Time frame:
1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · fold-rises
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to 1 Month After 13vPnC (Year 0)
fold-risesAll Participants
Serotype 1 (n=381)0.8 (0.70 to 1.02)
Serotype 3(n=374)0.9 (0.79 to 1.01)
Serotype 4(n=382)0.8 (0.73 to 0.95)
Serotype 5 (n=374)2.3 (1.92 to 2.80)
Serotype 6A(n=390)1.5 (1.31 to 1.74)
Serotype 6B(n=380)1.1 (1.00 to 1.31)
Serotype 7F(n=372)0.8 (0.67 to 0.96)
Serotype 9V(n=387)1.3 (1.08 to 1.60)
Serotype 14(n=383)1.0 (0.83 to 1.13)
Serotype 18C(n=381)1.0 (0.86 to 1.22)
Serotype 19A(n=378)1.0 (0.88 to 1.08)
Serotype 19F(n=369)2.4 (2.01 to 2.90)
Serotype 23F(n=368)4.0 (3.26 to 4.80)
Other pre-specifiedSerotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) Before 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMTs (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws. CI for GMTs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.

Time frame:
before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · titers
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) Before 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
titersAll Participants
Serotype 1:Before 13vPnC (Year 0),(n=384)6 (5.6 to 6.9)
Serotype 1: After 13vPnC (Year 5),(n=384)171 (145.4 to 200.4)
Serotype 3: Before 13vPnC (Year 0),(n=380)6 (5.6 to 6.9)
Serotype 3: After 13vPnC (Year 5),(n=380)60 (53.0 to 67.8)
Serotype 4 : Before 13vPnC (Year 0),(n=310)22 (16.3 to 28.9)
Serotype 4 : After 13vPnC (Year 5),(n=310)1558 (1379.0 to 1761.0)
Serotype 5 : Before 13vPnC (Year 0),(n=370)5 (4.6 to 5.4)
Serotype 5 :After 13vPnC (Year 5),(n=370)284 (241.8 to 333.1)
Serotype 6A : Before 13vPnC (Year 0),(n=356)18 (14.3 to 23.1)
Serotype 6A : After 13vPnC (Year 5),(n=356)4072 (3533.5 to 4692.1)
Serotype 6B : Before 13vPnC (Year 0),(n=333)53 (38.7 to 71.6)
Serotype 6B : After 13vPnC (Year 5),(n=333)3341 (2930.6 to 3809.9)
Serotype 7F: Before 13vPnC (Year 0),(n=330)10 (7.7 to 12.2)
Serotype 7F: After 13vPnC (Year 5),(n=330)1818 (1624.0 to 2035.0)
Serotype 9V: Before 13vPnC (Year 0),(n=352)28 (21.3 to 37.5)
Serotype 9V: After 13vPnC (Year 5),(n=352)1725 (1451.1 to 2050.8)
Serotype 14: Before 13vPnC (Year 0),(n=369)67 (50.8 to 87.2)
Serotype 14: After 13vPnC (Year 5),(n=369)1164 (1041.9 to 1300.8)
Serotype 18C: Before 13vPnC (Year 0),(n=361)20 (15.7 to 25.2)
Serotype 18C: After 13vPnC (Year 5),(n=361)1824 (1579.7 to 2105.6)
Serotype 19A: Before 13vPnC (Year 0),(n=348)28 (22.6 to 33.8)
Serotype 19A: After 13vPnC (Year 5),(n=348)849 (749.6 to 961.0)
Serotype 19F: Before 13vPnC (Year 0),(n=377)14 (11.3 to 16.7)
Serotype 19F: After 13vPnC (Year 5),(n=377)1106 (954.7 to 1281.3)
Serotype 23F: Before 13vPnC (Year 0),(n=350)9 (7.2 to 10.2)
Serotype 23F: After 13vPnC (Year 5),(n=350)1851 (1590.3 to 2155.3)
Other pre-specifiedSerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 0)

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before13vPnC (Year 0) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

Time frame:
before 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · fold-rises
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 0)
fold-risesAll Participants
Serotype 1 (n=384)27.5 (23.05 to 32.78)
Serotype 3(n=380)9.7 (8.34 to 11.19)
Serotype 4(n=310)71.8 (53.28 to 96.69)
Serotype 5 (n=370)57.0 (48.03 to 67.58)
Serotype 6A(n=356)224.1 (171.09 to 293.51)
Serotype 6B(n=333)63.5 (46.14 to 87.45)
Serotype 7F(n=330)188.0 (147.92 to 238.83)
Serotype 9V(n=352)61.0 (45.19 to 82.31)
Serotype 14(n=369)17.5 (13.40 to 22.86)
Serotype 18C(n=361)91.7 (71.33 to 117.84)
Serotype 19A(n=348)30.7 (24.99 to 37.77)
Serotype 19F(n=377)80.5 (64.90 to 99.92)
Serotype 23F(n=350)216.5 (172.97 to 270.87)
Other pre-specifiedSerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC (Year 0), 1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5)

Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of participants using a microcolony OPA (mcOPA) assay. GMT (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before, 1 month after 13vPnC (Year 0), at Years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) blood draws. CI for GMT were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. n=participants with valid and determinate assay results for the specified serotype at before, 1 month after 13vPnC (Year 0), at Years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) blood draws.

Time frame:
Before,1 month after 13vPnC (Year 0), 1, 2, 3, 4 years after initial vaccination (Year 0); before,1 month after 13vPnC (Year 5)
Reported as:
Geometric mean · titers
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Before and 1 Month After 13vPnC (Year 0), 1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5)
titersAll Participants
Serotype 1: Before 13vPnC dose Year 0 (n=92)6 (4.9 to 7.0)
Serotype 1: After 13vPnC dose at Year 0 (n=92)200 (143.5 to 278.0)
Serotype 1: Year 1 (n=125)19 (14.0 to 26.7)
Serotype 1: Year 2 (n=128)14 (10.1 to 18.2)
Serotype 1: Year 3 (n=128)11 (8.3 to 14.5)
Serotype 1: Year 4 (n=127)10 (7.4 to 12.4)
Serotype 1: Before 13vPnC dose Year 5 (n=126)10 (7.8 to 12.8)
Serotype 1: After 13vPnC dose at Year 5 (n=126)203 (158.5 to 260.6)
Serotype 3: Before 13vPnC dose Year 0 (n=90)6 (4.9 to 7.3)
Serotype 3: After 13vPnC dose Year 0 (n=91)63 (48.1 to 83.6)
Serotype 3: Year 1 (n=129)14 (10.7 to 17.2)
Serotype 3: Year 2 (n=129)12 (9.2 to 14.7)
Serotype 3: Year 3 (n=129)9 (7.1 to 10.7)
Serotype 3: Year 4 (n=128)9 (7.2 to 11.3)
Serotype 3: Before 13vPnC dose Year 5 (n=129)9 (7.3 to 11.7)
Serotype 3: After 13vPnC dose at Year 5 (n=128)55 (44.6 to 68.1)
Serotype 4: Before 13vPnC dose Year 0 (n=74)16 (8.8 to 27.3)
Serotype 4: After 13vPnC dose at Year 0 (n=91)1896 (1429.7 to 2514.2)
Serotype 4: Year 1 (n=126)442 (309.0 to 632.4)
Serotype 4: Year 2 (n=121)181 (117.1 to 278.7)
Serotype 4: Year 3 (n=125)137 (89.4 to 211.0)
Serotype 4: Year 4 (n=123)97 (62.2 to 151.5)
Serotype 4: Before 13vPnC dose Year 5 (n=125)92 (59.7 to 140.6)
Serotype 4: After 13vPnC dose at Year 5 (n=128)1574 (1340.7 to 1847.9)
Serotype 5: Before 13vPnC dose Year 0 (n=89)5 (4.1 to 5.2)
Serotype 5: After 13vPnC dose at Year 0 (n=93)145 (96.5 to 216.6)
Serotype 5: Year 1 (n=130)32 (22.8 to 43.7)
Serotype 5: Year 2 (n=128)20 (14.4 to 27.0)
Serotype 5: Year 3 (n=128)17 (12.3 to 23.0)
Serotype 5: Year 4 (n=128)14 (10.7 to 19.3)
Serotype 5: Before 13vPnC dose Year 5 (n=129)13 (9.9 to 17.8)
Serotype 5: After 13vPnC dose at Year 5 (n=128)273 (204.7 to 365.2)
Serotype 6A: Before 13vPnC dose Year 0 (n=87)16 (9.9 to 26.1)
Serotype 6A: After 13vPnC dose Year 0 (n=94)2158 (1456.8 to 3196.6)
Serotype 6A: Year 1 (n=126)748 (532.4 to 1051.3)
Serotype 6A: Year 2 (n=129)405 (275.0 to 595.8)
Serotype 6A: Year 3 (n=127)282 (187.7 to 424.1)
Serotype 6A: Year 4 (n=126)203 (134.6 to 306.1)
Serotype 6A: Before 13vPnC dose Year 5 (n=125)166 (107.5 to 255.3)
Serotype 6A: After 13vPnC dose Year 5 (n=129)3777 (2916.3 to 4891.2)
Serotype 6B: Before 13vPnC dose Year 0 (n=83)88 (46.7 to 165.8)
Serotype 6B: After 13vPnC dose Year 0 (n=93)2950 (2110.7 to 4123.5)
Serotype 6B: Year 1 (n=122)765 (562.2 to 1039.9)
Serotype 6B: Year 2 (n=121)505 (353.9 to 720.2)
Serotype 6B: Year 3 (n=120)373 (253.3 to 549.8)
Serotype 6B: Year 4 (n=115)326 (218.2 to 485.9)
Serotype 6B: Before 13vPnC dose Year 5 (n=123)229 (149.1 to 350.3)
Serotype 6B: After 13vPnC dose Year 5 (n=127)3804 (3216.1 to 4499.0)
Serotype 7F: Before 13vPnC dose Year 0 (n=80)13 (7.9 to 23.0)
Serotype 7F: After 13vPnC dose Year 0 (n=88)2265 (1563.6 to 3280.4)
Serotype 7F: Year 1 (n=129)515 (356.6 to 745.1)
Serotype 7F: Year 2 (n=128)279 (182.4 to 426.9)
Serotype 7F: Year 3 (n=125)253 (165.1 to 387.4)
Serotype 7F: Year 4 (n=127)175 (114.3 to 268.6)
Serotype 7F: Before 13vPnC dose Year 5 (n=124)155 (98.7 to 244.5)
Serotype 7F: After 13vPnC dose Year 5 (n=129)1932 (1585.5 to 2353.7)
Serotype 9V: Before 13vPnC dose Year 0 (n=88)17 (9.7 to 28.3)
Serotype 9V: After 13vPnC dose Year 0 (n=93)1202 (795.7 to 1816.4)
Serotype 9V: Year 1 (n=125)276 (173.2 to 440.3)
Serotype 9V: Year 2 (n=127)136 (83.4 to 221.5)
Serotype 9V: Year 3 (n=128)121 (75.2 to 194.7)
Serotype 9V: Year 4 (n=124)66 (39.8 to 108.7)
Serotype 9V: Before 13vPnC dose Year 5 (n=128)86 (53.1 to 139.9)
Serotype 9V: After 13vPnC dose Year 5 (n=127)1572 (1155.4 to 2139.2)
Serotype 14: Before 13vPnC dose Year 0 (n=87)74 (41.7 to 130.1)
Serotype 14: After 13vPnC dose Year 0 (n=90)1436 (1036.7 to 1989.0)
Serotype 14: Year 1 (n=124)541 (394.3 to 741.1)
Serotype 14: Year 2 (n=125)446 (326.5 to 609.0)
Serotype 14: Year 3 (n=124)416 (302.8 to 571.3)
Serotype 14: Year 4 (n=125)341 (241.9 to 481.4)
Serotype 14: Before 13vPnC dose Year 5 (n=127)335 (244.8 to 457.6)
Serotype 14: After 13vPnC dose Year 5 (n=128)1238 (1046.4 to 1464.2)
Serotype 18C: Before 13vPnC dose Year 0 (n=82)18 (11.4 to 29.2)
Serotype 18C: After 13vPnC dose Year 0 (n=92)1189 (766.6 to 1843.2)
Serotype 18C: Year 1 (n=127)301 (206.2 to 440.4)
Serotype 18C: Year 2 (n=123)170 (115.2 to 251.6)
Serotype 18C: Year 3 (n=129)115 (76.7 to 171.2)
Serotype 18C: Year 4 (n=126)102 (67.6 to 154.9)
Serotype 18C: Before 13vPnC dose Year 5 (n=127)99 (65.9 to 148.1)
Serotype 18C: After 13vPnC dose Year 5 (n=127)1580 (1289.0 to 1937.4)
Serotype 19A: Before 13vPnC dose Year 0 (n=84)24 (15.7 to 37.1)
Serotype 19A: After 13vPnC dose Year 0 (n=92)727 (551.4 to 957.4)
Serotype 19A: Year 1 (n=130)193 (145.9 to 255.4)
Serotype 19A: Year 2 (n=127)135 (100.4 to 181.9)
Serotype 19A: Year 3 (n=129)105 (76.6 to 143.3)
Serotype 19A: Year 4 (n=129)97 (72.0 to 131.6)
Serotype 19A: Before 13vPnC dose Year 5 (n=130)97 (71.7 to 132.3)
Serotype 19A: After 13vPnC dose Year 5 (n=128)874 (729.8 to 1046.1)
Serotype 19F: Before 13vPnC dose Year 0 (n=94)14 (9.3 to 21.1)
Serotype 19F: After 13vPnC dose Year 0 (n=91)448 (298.8 to 670.5)
Serotype 19F: Year 1 (n=124)85 (55.7 to 131.0)
Serotype 19F: Year 2 (n=128)44 (28.9 to 67.3)
Serotype 19F: Year 3 (n=128)35 (23.0 to 54.4)
Serotype 19F: Year 4 (n=125)29 (19.2 to 44.0)
Serotype 19F: Before 13vPnC dose Year 5 (n=125)24 (15.9 to 36.1)
Serotype 19F: After 13vPnC dose Year 5 (n=125)1112 (882.3 to 1400.5)
Serotype 23F: Before 13vPnC dose Year 0 (n=84)9 (6.1 to 13.3)
Serotype 23F: After 13vPnC dose Year 0 (n=89)396 (242.7 to 646.6)
Serotype 23F: Year 1 (n=127)116 (78.9 to 171.6)
Serotype 23F: Year 2 (n=124)95 (64.1 to 141.0)
Serotype 23F: Year 3 (n=128)60 (40.4 to 88.0)
Serotype 23F: Year 4 (n=127)54 (36.8 to 78.6)
Serotype 23F: Before 13vPnC dose Year 5 (n=127)48 (33.0 to 71.1)
Serotype 23F: After 13vPnC dose Year 5 (n=128)1642 (1263.2 to 2133.5)
Other pre-specifiedSerotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC (Year 0),1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5) Relative to Before 13vPnC (Year 0)

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before to 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both the baseline and the various time points.

Time frame:
Before, 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5)
Reported as:
Geometric mean · fold-rises
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC (Year 0),1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5) Relative to Before 13vPnC (Year 0)
fold-risesAll Participants
Serotype 1:After 13vPnC dose at Year 0 (n=89)34.0 (24.24 to 47.66)
Serotype 1: Year 1 (n= 90)3.5 (2.45 to 5.00)
Serotype 1: Year 2 (n=91)2.4 (1.72 to 3.26)
Serotype 1: Year 3 (n= 92)1.8 (1.38 to 2.47)
Serotype 1: Year 4 (n= 90)1.6 (1.24 to 2.09)
Serotype 1: Before 13vPnC dose Year 5 (n=89)1.7 (1.26 to 2.16)
Serotype 1: After 13vPnC dose at Year 5 (n=89)39.3 (28.69 to 53.81)
Serotype 3: After 13vPnC dose at Year 0 (n=87)10.4 (7.65 to 14.23)
Serotype 3: Year 1 (n=89)2.0 (1.59 to 2.58)
Serotype 3: Year 2 (n=89)1.6 (1.29 to 2.01)
Serotype 3: Year 3 (n=89)1.3 (1.04 to 1.56)
Serotype 3: Year 4 (n=89)1.4 (1.15 to 1.76)
Serotype 3: Before 13vPnC dose Year 5 (n=90)1.5 (1.14 to 1.86)
Serotype 3: After 13vPnC dose at Year 5 (n=89)9.1 (6.93 to 12.07)
Serotype 4: After 13vPnC dose at Year 0 (n=72)118.9 (65.63 to 215.39)
Serotype 4: Year 1 (n=74)21.3 (11.90 to 38.06)
Serotype 4: Year 2 (n=71)8.3 (4.66 to 14.95)
Serotype 4: Year 3 (n=70)6.5 (3.75 to 11.15)
Serotype 4: Year 4 (n=71)4.6 (2.73 to 7.63)
Serotype 4: Before 13vPnC dose Year 5 (n=71)4.7 (2.80 to 7.74)
Serotype 4: After 13vPnC dose at Year 5 (n=73)98.7 (54.38 to 179.10)
Serotype 5: After 13vPnC dose at Year 0 (n=87)29.5 (19.21 to 45.45)
Serotype 5: Year 1 (n=89)6.1 (4.18 to 8.91)
Serotype 5: Year 2 (n=88)3.7 (2.57 to 5.40)
Serotype 5: Year 3 (n=88)2.9 (2.05 to 4.19)
Serotype 5: Year 4 (n=88)2.6 (1.84 to 3.59)
Serotype 5: Before 13vPnC dose Year 5 (n=88)2.3 (1.67 to 3.29)
Serotype 5: After 13vPnC dose at Year 5 (n=87)60.6 (42.73 to 86.06)
Serotype 6A: After 13vPnC dose Year 0 (n=86)126.8 (69.14 to 232.51)
Serotype 6A: Year 1 (n=85)38.3 (22.35 to 65.79)
Serotype 6A: Year 2 (n=87)21.9 (12.98 to 36.99)
Serotype 6A: Year 3 (n=86)14.8 (8.83 to 24.79)
Serotype 6A: Year 4 (n=85)11.7 (7.00 to 19.62)
Serotype 6A: Before 13vPnC dose Year 5 (n=85)9.2 (5.40 to 15.81)
Serotype 6A: After 13vPnC dose Year 5 (n=86)219.2 (123.97 to 387.54)
Serotype 6B: After 13vPnC dose Year 0 (n=81)33.3 (17.17 to 64.74)
Serotype 6B: Year 1 (n=78)8.9 (4.88 to 16.21)
Serotype 6B: Year 2 (n=78)5.7 (3.18 to 10.14)
Serotype 6B: Year 3 (n=77)4.3 (2.33 to 7.98)
Serotype 6B: Year 4 (n=73)3.3 (1.91 to 5.75)
Serotype 6B: Before 13vPnC dose Year 5 (n=81)2.9 (1.63 to 5.28)
Serotype 6B: After 13vPnC dose Year 5 (n=81)38.8 (19.92 to 75.61)
Serotype 7F: After 13vPnC dose Year 0 (n=75)168.6 (88.78 to 320.29)
Serotype 7F: Year 1 (n=80)37.1 (19.84 to 69.34)
Serotype 7F: Year 2 (n=78)18.7 (10.16 to 34.57)
Serotype 7F: Year 3 (n=76)17.8 (9.69 to 32.66)
Serotype 7F: Year 4 (n=78)10.4 (5.69 to 18.93)
Serotype 7F: Before 13vPnC dose Year 5 (n=77)8.4 (4.57 to 15.56)
Serotype 7F: After 13vPnC dose Year 5 (n=80)163.6 (95.30 to 280.70)
Serotype 9V: After 13vPnC dose Year 0 (n=86)68.2 (37.54 to 123.92)
Serotype 9V: Year 1 (n=86)12.2 (6.94 to 21.55)
Serotype 9V: Year 2 (n=87)5.6 (3.30 to 9.63)
Serotype 9V: Year 3 (n=88)5.3 (3.20 to 8.80)
Serotype 9V: Year 4 (n=84)3.0 (1.79 to 5.00)
Serotype 9V: Before 13vPnC dose Year 5 (n=87)3.8 (2.19 to 6.66)
Serotype 9V: After 13vPnC dose Year 5 (n=86)99.3 (54.99 to 179.41)
Serotype 14: After 13vPnC dose Year 0 (n=83)22.4 (12.42 to 40.22)
Serotype 14: Year 1 (n=84)7.3 (4.35 to 12.22)
Serotype 14: Year 2 (n=85)6.2 (3.86 to 10.11)
Serotype 14: Year 3 (n=82)5.2 (3.12 to 8.80)
Serotype 14: Year 4 (n=84)5.5 (3.26 to 9.42)
Serotype 14: Before 13vPnC dose Year 5 (n=86)4.7 (2.85 to 7.86)
Serotype 14: After 13vPnC dose Year 5 (n=86)19.9 (11.37 to 35.00)
Serotype 18C: After 13vPnC dose Year 0 (n=79)58.2 (31.53 to 107.35)
Serotype 18C: Year 1 (n=81)12.3 (7.45 to 20.29)
Serotype 18C: Year 2 (n=81)6.2 (3.73 to 10.34)
Serotype 18C: Year 3 (n=81)4.5 (2.82 to 7.30)
Serotype 18C: Year 4 (n=79)3.9 (2.46 to 6.22)
Serotype 18C: Before 13vPnC dose Year 5 (n=81)3.9 (2.40 to 6.28)
Serotype 18C: After 13vPnC dose Year 5 (n=79)82.7 (50.04 to 136.70)
Serotype 19A: After 13vPnC dose Year 0 (n=81)28.4 (18.04 to 44.69)
Serotype 19A: Year 1 (n=84)7.3 (4.72 to 11.16)
Serotype 19A: Year 2 (n=82)5.4 (3.55 to 8.18)
Serotype 19A: Year 3 (n=84)4.1 (2.72 to 6.10)
Serotype 19A: Year 4 (n=84)3.7 (2.42 to 5.61)
Serotype 19A: Before 13vPnC dose Year 5 (n=84)3.8 (2.45 to 5.99)
Serotype 19A: After 13vPnC dose Year 5 (n=83)36.4 (23.40 to 56.57)
Serotype 19F: After 13vPnC dose Year 0 (n=90)32.8 (20.67 to 51.98)
Serotype 19F: Year 1 (n=91)6.3 (4.08 to 9.86)
Serotype 19F: Year 2 (n=93)3.9 (2.58 to 6.02)
Serotype 19F: Year 3 (n=92)2.7 (1.76 to 4.09)
Serotype 19F: Year 4 (n=91)2.4 (1.62 to 3.56)
Serotype 19F: Before 13vPnC dose Year 5 (n=90)1.9 (1.26 to 2.83)
Serotype 19F: After 13vPnC dose Year 5 (n=89)81.6 (52.36 to 127.08)
Serotype 23F: After 13vPnC dose Year 0 (n=79)41.2 (23.36 to 72.69)
Serotype 23F: Year 1 (n=84)12.6 (7.69 to 20.62)
Serotype 23F: Year 2 (n=81)9.6 (5.81 to 15.78)
Serotype 23F: Year 3 (n=84)6.6 (4.13 to 10.41)
Serotype 23F: Year 4 (n=84)5.8 (3.68 to 9.26)
Serotype 23F: Before 13vPnC dose Year 5 (n=83)5.3 (3.31 to 8.53)
Serotype 23F: After 13vPnC dose Year 5 (n=82)194.0 (115.99 to 324.32)
Other pre-specifiedSerotype-Specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) 1 Month After 13vPnC (Year 5)

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 1 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
1 month after 13vPnC (Year 5)
Reported as:
Geometric mean · microgram per milliliter(mcg/mL)
Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) 1 Month After 13vPnC (Year 5)
microgram per milliliter(mcg/mL)13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Serotype 1 (n=357, 345)5.92 (5.33 to 6.57)5.83 (5.20 to 6.55)
Serotype 3(n=343, 338)0.69 (0.62 to 0.76)0.72 (0.65 to 0.80)
Serotype 4(n=357,345)4.90 (4.42 to 5.44)4.77 (4.22 to 5.39)
Serotype 5(n=357,345)7.49 (6.71 to 8.35)8.02 (7.16 to 8.99)
Serotype 6A(n=357,345)13.59 (12.01 to 15.39)13.45 (11.67 to 15.51)
Serotype 6B(n=355,345)20.18 (17.74 to 22.96)21.76 (18.97 to 24.96)
Serotype 7F(n=357,345)8.48 (7.72 to 9.30)8.70 (7.91 to 9.58)
Serotype 9V(n=357,345)5.91 (5.37 to 6.51)6.35 (5.74 to 7.02)
Serotype 14(n=357,345)15.57 (13.94 to 17.39)16.39 (14.70 to 18.28)
Serotype 18C(n=357,345)7.77 (7.06 to 8.55)8.46 (7.58 to 9.44)
Serotype 19A(n=357,345)16.77 (15.09 to 18.64)17.97 (16.14 to 20.01)
Serotype 19F(n=357,345)16.83 (14.86 to 19.06)18.18 (15.77 to 20.96)
Serotype 23F(n=357,345)18.15 (15.87 to 20.76)20.25 (17.57 to 23.32)
Statistical analysis
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.01 · 95% CI 0.87 to 1.18
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.95 · 95% CI 0.82 to 1.10
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.03 · 95% CI 0.88 to 1.21
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.93 · 95% CI 0.80 to 1.09
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 1.01 · 95% CI 0.84 to 1.22
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.93 · 95% CI 0.77 to 1.12
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.97 · 95% CI 0.85 to 1.11
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.93 · 95% CI 0.81 to 1.07
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.95 · 95% CI 0.81 to 1.11
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.92 · 95% CI 0.79 to 1.06
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.93 · 95% CI 0.80 to 1.08
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.93 · 95% CI 0.77 to 1.12
  • 13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5) vs Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5) · Geometric mean ratio: 0.90 · 95% CI 0.74 to 1.09
Other pre-specifiedSerotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) Before 13vPnC (Year 5) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both Year 5 time points.

Time frame:
before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · mcg/mL
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) Before 13vPnC (Year 5) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
mcg/mLAll Participants
Serotype 1:Before 13vPnC (Year 5),(n=665)1.27 (1.16 to 1.40)
Serotype 1: After 13vPnC (Year 5),(n=665)5.87 (5.42 to 6.36)
Serotype 3: Before 13vPnC (Year 5),(n=623)0.33 (0.30 to 0.37)
Serotype 3: After 13vPnC (Year 5),(n=623)0.71 (0.65 to 0.76)
Serotype 4 : Before 13vPnC (Year 5),(n=663)0.67 (0.60 to 0.74)
Serotype 4 : After 13vPnC (Year 5),(n=663)4.83 (4.45 to 5.24)
Serotype 5 : Before 13vPnC (Year 5),(n=671)2.65 (2.45 to 2.87)
Serotype 5 :After 13vPnC (Year 5),(n=671)7.76 (7.16 to 8.41)
Serotype 6A : Before 13vPnC (Year 5),(n=671)2.52 (2.33 to 2.73)
Serotype 6A : After 13vPnC (Year 5),(n=671)13.51 (12.28 to 14.86)
Serotype 6B : Before 13vPnC (Year 5),(n=668)3.12 (2.86 to 3.41)
Serotype 6B : After 13vPnC (Year 5),(n=668)21.04 (19.12 to 23.16)
Serotype 7F: Before 13vPnC (Year 5),(n=671)2.52 (2.31 to 2.76)
Serotype 7F: After 13vPnC (Year 5),(n=671)8.72 (8.16 to 9.33)
Serotype 9V: Before 13vPnC (Year 5),(n=672)2.11 (1.96 to 2.28)
Serotype 9V: After 13vPnC (Year 5),(n=672)6.14 (5.71 to 6.59)
Serotype 14: Before 13vPnC (Year 5),(n=672)5.17 (4.69 to 5.70)
Serotype 14: After 13vPnC (Year 5),(n=672)16.26 (15.03 to 17.58)
Serotype 18C: Before 13vPnC (Year 5),(n=672)2.55 (2.34 to 2.78)
Serotype 18C: After 13vPnC (Year 5),(n=672)8.10 (7.52 to 8.72)
Serotype 19A: Before 13vPnC (Year 5),(n=671)5.47 (5.07 to 5.89)
Serotype 19A: After 13vPnC (Year 5),(n=671)17.29 (16.03 to 18.65)
Serotype 19F: Before 13vPnC (Year 5),(n=664)2.24 (2.02 to 2.47)
Serotype 19F: After 13vPnC (Year 5),(n=664)17.73 (16.10 to 19.53)
Serotype 23F: Before 13vPnC (Year 5),(n=671)2.50 (2.29 to 2.73)
Serotype 23F: After 13vPnC (Year 5),(n=671)19.23 (17.45 to 21.20)
Other pre-specifiedSerotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 5)

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before 13vPnC (Year 5) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 5) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

Time frame:
before 13vPnC (Year 5), 1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · fold-rises
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 5)
fold-risesAll Participants
Serotype 1 (n=665)4.62 (4.22 to 5.05)
Serotype 3(n=623)2.11 (1.99 to 2.24)
Serotype 4(n=663)7.24 (6.60 to 7.95)
Serotype 5 (n=671)2.93 (2.75 to 3.12)
Serotype 6A(n=671)5.35 (4.92 to 5.82)
Serotype 6B(n=668)6.74 (6.19 to 7.34)
Serotype 7F(n=671)3.46 (3.20 to 3.74)
Serotype 9V(n=672)2.90 (2.74 to 3.08)
Serotype 14(n=672)3.14 (2.89 to 3.42)
Serotype 18C(n=672)3.18 (2.96 to 3.41)
Serotype 19A(n=671)3.16 (2.95 to 3.39)
Serotype 19F(n=664)7.93 (7.21 to 8.72)
Serotype 23F(n=671)7.69 (7.05 to 8.39)
Other pre-specifiedSerotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) 1 Month After 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points

Time frame:
1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · mcg/mL
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) 1 Month After 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
mcg/mLAll Participants
Serotype 1:After 13vPnC (Year 0),(n=389)4.77 (4.10 to 5.54)
Serotype 1: After 13vPnC (Year 5),(n=389)5.88 (5.32 to 6.50)
Serotype 3: After 13vPnC (Year 0),(n=378)1.26 (1.13 to 1.40)
Serotype 3: After 13vPnC (Year 5),(n=378)0.74 (0.67 to 0.81)
Serotype 4 : After 13vPnC (Year 0),(n=387)2.90 (2.51 to 3.36)
Serotype 4 : After 13vPnC (Year 5),(n=387)5.13 (4.64 to 5.68)
Serotype 5 : After 13vPnC (Year 0),(n=390)6.52 (5.72 to 7.44)
Serotype 5 :After 13vPnC (Year 5),(n=390)8.25 (7.40 to 9.20)
Serotype 6A : After 13vPnC (Year 0),(n=390)6.13 (5.41 to 6.94)
Serotype 6A : After 13vPnC (Year 5),(n=390)13.52 (11.94 to 15.31)
Serotype 6B : After 13vPnC (Year 0),(n=390)8.87 (7.77 to 10.14)
Serotype 6B : After 13vPnC (Year 5),(n=390)20.70 (18.31 to 23.39)
Serotype 7F: After 13vPnC (Year 0),(n=390)9.24 (8.16 to 10.47)
Serotype 7F: After 13vPnC (Year 5),(n=390)8.40 (7.68 to 9.19)
Serotype 9V: After 13vPnC (Year 0),(n=391)5.83 (5.17 to 6.56)
Serotype 9V: After 13vPnC (Year 5),(n=391)6.07 (5.53 to 6.65)
Serotype 14: After 13vPnC (Year 0),(n=391)11.98 (10.33 to 13.91)
Serotype 14: After 13vPnC (Year 5),(n=391)15.04 (13.57 to 16.66)
Serotype 18C: After 13vPnC (Year 0),(n=390)11.64 (10.20 to 13.29)
Serotype 18C: After 13vPnC (Year 5),(n=390)8.25 (7.47 to 9.12)
Serotype 19A: After 13vPnC (Year 0),(n=391)17.43 (15.51 to 19.59)
Serotype 19A: After 13vPnC (Year 5),(n=391)18.48 (16.68 to 20.48)
Serotype 19F: After 13vPnC (Year 0),(n=388)6.56 (5.66 to 7.60)
Serotype 19F: After 13vPnC (Year 5),(n=388)18.26 (16.14 to 20.66)
Serotype 23F: After 13vPnC (Year 0),(n=391)8.03 (6.91 to 9.32)
Serotype 23F: After 13vPnC (Year 5),(n=391)20.17 (17.81 to 22.83)
Other pre-specifiedSerotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to 1 Month After 13vPnC (Year 0)

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both 1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

Time frame:
1 month after 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · fold-rises
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to 1 Month After 13vPnC (Year 0)
fold-risesAll Participants
Serotype 1 (n=389)1.23 (1.07 to 1.42)
Serotype 3(n=378)0.59 (0.54 to 0.64)
Serotype 4(n=387)1.77 (1.56 to 2.01)
Serotype 5 (n=390)1.26 (1.14 to 1.41)
Serotype 6A(n=390)2.21 (1.97 to 2.47)
Serotype 6B(n=390)2.33 (2.08 to 2.61)
Serotype 7F(n=390)0.91 (0.81 to 1.02)
Serotype 9V(n=391)1.04 (0.95 to 1.14)
Serotype 14(n=391)1.25 (1.10 to 1.43)
Serotype 18C(n=390)0.71 (0.64 to 0.79)
Serotype 19A(n=391)1.06 (0.96 to 1.17)
Serotype 19F(n=388)2.78 (2.44 to 3.17)
Serotype 23F(n=391)2.51 (2.23 to 2.83)
Other pre-specifiedSerotype-Specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) Before 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for adult participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5) blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Participants in this population must have immunogenicity data at both the Year 0 and Year 5 time points.

Time frame:
before 13vPnC (Year 0) and 1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · mcg/mL
Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs) Before 13vPnC (Year 0) and 1 Month After 13vPnC Re-vaccinated Dose (Year 5)
mcg/mLAll Participants
Serotype 1:Before 13vPnC (Year 0),(n=380)0.44 (0.38 to 0.50)
Serotype 1: After 13vPnC (Year 5),(n=380)5.86 (5.29 to 6.48)
Serotype 3: Before 13vPnC (Year 0),(n=368)0.47 (0.42 to 0.53)
Serotype 3: After 13vPnC (Year 5),(n=368)0.74 (0.67 to 0.81)
Serotype 4 : Before 13vPnC (Year 0),(n=373)0.22 (0.19 to 0.26)
Serotype 4 : After 13vPnC (Year 5),(n=373)5.21 (4.71 to 5.77)
Serotype 5 : Before 13vPnC (Year 0),(n=387)1.79 (1.65 to 1.95)
Serotype 5 :After 13vPnC (Year 5),(n=387)8.32 (7.46 to 9.27)
Serotype 6A : Before 13vPnC (Year 0),(n=386)1.56 (1.42 to 1.71)
Serotype 6A : After 13vPnC (Year 5),(n=386)13.63 (12.03 to 15.45)
Serotype 6B : Before 13vPnC (Year 0),(n=383)1.76 (1.58 to 1.96)
Serotype 6B : After 13vPnC (Year 5),(n=383)21.09 (18.66 to 23.84)
Serotype 7F: Before 13vPnC (Year 0),(n=384)0.70 (0.62 to 0.79)
Serotype 7F: After 13vPnC (Year 5),(n=384)8.41 (7.70 to 9.19)
Serotype 9V: Before 13vPnC (Year 0),(n=387)0.87 (0.79 to 0.96)
Serotype 9V: After 13vPnC (Year 5),(n=387)6.07 (5.53 to 6.66)
Serotype 14: Before 13vPnC (Year 0),(n=389)1.95 (1.69 to 2.26)
Serotype 14: After 13vPnC (Year 5),(n=389)14.98 (13.51 to 16.61)
Serotype 18C: Before 13vPnC (Year 0),(n=388)0.82 (0.72 to 0.94)
Serotype 18C: After 13vPnC (Year 5),(n=388)8.24 (7.45 to 9.11)
Serotype 19A: Before 13vPnC (Year 0),(n=388)2.92 (2.66 to 3.22)
Serotype 19A: After 13vPnC (Year 5),(n=388)18.52 (16.71 to 20.53)
Serotype 19F: Before 13vPnC (Year 0),(n=371)1.17 (1.03 to 1.33)
Serotype 19F: After 13vPnC (Year 5),(n=371)18.68 (16.46 to 21.19)
Serotype 23F: Before 13vPnC (Year 0),(n=382)0.97 (0.86 to 1.09)
Serotype 23F: After 13vPnC (Year 5),(n=382)20.53 (18.14 to 23.23)
Other pre-specifiedSerotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 0)

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from Before 13vPnC (Year 0) to 1 month after 13vPnC re-vaccinated dose (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5) blood draws.

Time frame:
Before 13vPnC (Year 0),1 month after 13vPnC re-vaccinated dose (Year 5)
Reported as:
Geometric mean · fold-rises
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC Re-vaccinated Dose (Year 5) Relative to Before 13vPnC (Year 0)
fold-risesAll Participants
Serotype 1 (n=380)13.37 (11.66 to 15.33)
Serotype 3(n=368)1.57 (1.43 to 1.73)
Serotype 4(n=373)23.59 (20.21 to 27.55)
Serotype 5 (n=387)4.64 (4.17 to 5.16)
Serotype 6A(n=386)8.74 (7.63 to 10.00)
Serotype 6B(n=383)11.96 (10.46 to 13.68)
Serotype 7F(n=384)11.96 (10.53 to 13.57)
Serotype 9V(n=387)6.97 (6.29 to 7.73)
Serotype 14(n=389)7.68 (6.62 to 8.92)
Serotype 18C(n=388)10.04 (8.84 to 11.40)
Serotype 19A(n=388)6.33 (5.66 to 7.09)
Serotype 19F(n=371)15.95 (13.69 to 18.57)
Serotype 23F(n=382)21.18 (18.50 to 24.25)
Other pre-specifiedGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC (Year 0), 1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5)

Participants received either 0.5 mL dose of 13vPnC intramuscular injection into the deltoid muscle of the left arm along with 0.5-mL TIV intramuscular injection into the deltoid muscle of the right arm at Year 0 on Day 1(Dose1, 13vPnC+TIV), or placebo matched to 13vPnC intramuscular injection into the deltoid muscle of the left arm along with 0.5-mL TIV intramuscular injection into the deltoid muscle of the right arm at Year 0 on Day 1(Dose 1, placebo+TIV). Placebo matched to 13vPnC was administered 1 month after(Dose 2, placebo), or 13vPnC was administered 1 month after (Dose 2, 13vPnC).Participants were further followed-up for 1 month,then attended a 6-month follow-up visit for safety.Participants were then followed-up yearly for 4 years.Participants then received 0.5 mL dose of 13vPnC intramuscular injection into the deltoid muscle of the left arm 5 years after initial vaccination.Participants were further followed-up for 1 month, then attended a 6-month follow-up visit for safety.

Time frame:
Before,1 month after 13vPnC (Year 0), 1, 2, 3, 4 years after initial vaccination (Year 0); before,1 month after 13vPnC (Year 5)
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before and 1 Month After 13vPnC (Year 0), 1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5)
mcg/mLAll Participants
Serotype 1: Before 13vPnC dose Year 0 (n=79)0.37 (0.28 to 0.49)
Serotype 1: After 13vPnC dose at Year 0 (n=83)4.53 (3.33 to 6.18)
Serotype 1: Year 1 (n=119)1.96 (1.55 to 2.48)
Serotype 1: Year 2 (n=124)1.56 (1.25 to 1.96)
Serotype 1: Year 3 (n=126)1.34 (1.08 to 1.66)
Serotype 1: Year 4 (n=125)1.32 (1.06 to 1.63)
Serotype 1: Before 13vPnC dose Year 5 (n=125)1.18 (0.95 to 1.47)
Serotype 1: After 13vPnC dose at Year 5 (n=125)6.08 (5.20 to 7.11)
Serotype 3: Before 13vPnC dose Year 0 (n=81)0.42 (0.33 to 0.53)
Serotype 3: After 13vPnC dose Year 0 (n=82)1.15 (0.92 to 1.44)
Serotype 3: Year 1 (n=115)0.37 (0.30 to 0.46)
Serotype 3: Year 2 (n=122)0.34 (0.27 to 0.42)
Serotype 3: Year 3 (n=119)0.30 (0.25 to 0.37)
Serotype 3: Year 4 (n=117)0.31 (0.25 to 0.38)
Serotype 3: Before 13vPnC dose Year 5 (n=117)0.30 (0.24 to 0.38)
Serotype 3: After 13vPnC dose at Year 5 (n=121)0.66 (0.55 to 0.79)
Serotype 4: Before 13vPnC dose Year 0 (n=80)0.19 (0.14 to 0.25)
Serotype 4: After 13vPnC dose at Year 0 (n=82)2.41 (1.74 to 3.35)
Serotype 4: Year 1 (n=118)0.98 (0.77 to 1.26)
Serotype 4: Year 2 (n=123)0.77 (0.61 to 0.98)
Serotype 4: Year 3 (n=125)0.67 (0.53 to 0.85)
Serotype 4: Year 4 (n=125)0.64 (0.50 to 0.82)
Serotype 4: Before 13vPnC dose Year 5 (n=122)0.58 (0.46 to 0.74)
Serotype 4: After 13vPnC dose at Year 5 (n=125)4.62 (3.92 to 5.45)
Serotype 5: Before 13vPnC dose Year 0 (n=82)1.40 (1.17 to 1.69)
Serotype 5: After 13vPnC dose at Year 0 (n=83)5.80 (4.40 to 7.64)
Serotype 5: Year 1 (n=118)3.10 (2.58 to 3.73)
Serotype 5: Year 2 (n=124)2.62 (2.19 to 3.14)
Serotype 5: Year 3 (n=126)2.40 (2.01 to 2.86)
Serotype 5: Year 4 (n=125)2.44 (2.05 to 2.91)
Serotype 5: Before 13vPnC dose Year 5 (n=125)2.41 (2.01 to 2.88)
Serotype 5: After 13vPnC dose at Year 5 (n=125)7.14 (5.95 to 8.57)
Serotype 6A: Before 13vPnC dose Year 0 (n=82)1.34 (1.09 to 1.66)
Serotype 6A: After 13vPnC dose Year 0 (n=83)5.74 (4.29 to 7.68)
Serotype 6A: Year 1 (n=119)3.64 (2.95 to 4.50)
Serotype 6A: Year 2 (n=124)3.10 (2.54 to 3.79)
Serotype 6A: Year 3 (n=126)2.76 (2.26 to 3.38)
Serotype 6A: Year 4 (n=126)2.74 (2.26 to 3.32)
Serotype 6A: Before 13vPnC dose Year 5 (n=125)2.63 (2.16 to 3.21)
Serotype 6A: After 13vPnC dose Year 5 (n=125)14.31 (11.43 to 17.93)
Serotype 6B: Before 13vPnC dose Year 0 (n=81)1.56 (1.23 to 1.97)
Serotype 6B: After 13vPnC dose Year 0 (n=83)8.24 (6.17 to 11.00)
Serotype 6B: Year 1 (n=119)4.96 (3.97 to 6.20)
Serotype 6B: Year 2 (n=124)3.97 (3.23 to 4.88)
Serotype 6B: Year 3 (n=126)3.58 (2.91 to 4.41)
Serotype 6B: Year 4 (n=126)3.53 (2.88 to 4.31)
Serotype 6B: Before 13vPnC dose Year 5 (n=125)3.18 (2.56 to 3.93)
Serotype 6B: After 13vPnC dose Year 5 (n=124)21.61 (17.55 to 26.60)
Serotype 7F: Before 13vPnC dose Year 0 (n=81)0.64 (0.51 to 0.81)
Serotype 7F: After 13vPnC dose Year 0 (n=83)9.14 (6.78 to 12.31)
Serotype 7F: Year 1 (n=119)3.82 (3.05 to 4.79)
Serotype 7F: Year 2 (n=124)3.10 (2.46 to 3.89)
Serotype 7F: Year 3 (n=126)2.58 (2.08 to 3.19)
Serotype 7F: Year 4 (n=126)2.55 (2.05 to 3.18)
Serotype 7F: Before 13vPnC dose Year 5 (n=124)2.36 (1.90 to 2.93)
Serotype 7F: After 13vPnC dose Year 5 (n=125)8.05 (6.68 to 9.71)
Serotype 9V: Before 13vPnC dose Year 0 (n=80)0.77 (0.63 to 0.95)
Serotype 9V: After 13vPnC dose Year 0 (n=83)4.58 (3.62 to 5.81)
Serotype 9V: Year 1 (n=119)2.84 (2.39 to 3.37)
Serotype 9V: Year 2 (n=124)2.37 (1.99 to 2.81)
Serotype 9V: Year 3 (n=126)2.16 (1.82 to 2.56)
Serotype 9V: Year 4 (n=126)2.09 (1.76 to 2.47)
Serotype 9V: Before 13vPnC dose Year 5 (n=125)1.97 (1.67 to 2.34)
Serotype 9V: After 13vPnC dose Year 5 (n=125)5.99 (5.14 to 6.98)
Serotype 14: Before 13vPnC dose Year 0 (n=82)2.21 (1.64 to 2.97)
Serotype 14: After 13vPnC dose Year 0 (n=83)14.48 (10.72 to 19.57)
Serotype 14: Year 1 (n=119)7.71 (6.07 to 9.80)
Serotype 14: Year 2 (n=124)6.82 (5.47 to 8.49)
Serotype 14: Year 3 (n=126)5.71 (4.50 to 7.25)
Serotype 14: Year 4 (n=126)5.31 (4.22 to 6.69)
Serotype 14: Before 13vPnC dose Year 5 (n=125)5.30 (4.20 to 6.70)
Serotype 14: After 13vPnC dose Year 5 (n=125)16.85 (14.07 to 20.18)
Serotype 18C: Before 13vPnC dose Year 0 (n=82)0.81 (0.62 to 1.07)
Serotype 18C: After 13vPnC dose Year 0 (n=83)8.11 (6.03 to 10.89)
Serotype 18C: Year 1 (n=119)3.45 (2.85 to 4.18)
Serotype 18C: Year 2 (n=124)2.82 (2.35 to 3.38)
Serotype 18C: Year 3 (n=126)2.38 (1.98 to 2.86)
Serotype 18C: Year 4 (n=126)2.44 (2.07 to 2.88)
Serotype 18C: Before 13vPnC dose Year 5 (n=125)2.26 (1.89 to 2.71)
Serotype 18C: After 13vPnC dose Year 5 (n=125)6.94 (5.92 to 8.12)
Serotype 19A: Before 13vPnC dose Year 0 (n=82)2.57 (2.13 to 3.11)
Serotype 19A: After 13vPnC dose Year 0 (n=83)14.11 (11.28 to 17.64)
Serotype 19A: Year 1 (n=119)6.95 (5.78 to 8.35)
Serotype 19A: Year 2 (n=124)6.13 (5.19 to 7.25)
Serotype 19A: Year 3 (n=126)5.60 (4.73 to 6.63)
Serotype 19A: Year 4 (n=126)5.47 (4.65 to 6.45)
Serotype 19A: Before 13vPnC dose Year 5 (n=125)5.11 (4.32 to 6.05)
Serotype 19A: After 13vPnC dose Year 5 (n=125)15.77 (13.25 to 18.78)
Serotype 19F: Before 13vPnC dose Year 0 (n=78)0.99 (0.75 to 1.29)
Serotype 19F: After 13vPnC dose Year 0 (n=83)5.64 (4.16 to 7.66)
Serotype 19F: Year 1 (n=118)2.87 (2.29 to 3.60)
Serotype 19F: Year 2 (n=121)2.55 (2.05 to 3.16)
Serotype 19F: Year 3 (n=124)2.28 (1.84 to 2.83)
Serotype 19F: Year 4 (n=125)2.26 (1.83 to 2.81)
Serotype 19F: Before 13vPnC dose Year 5 (n=123)2.10 (1.66 to 2.66)
Serotype 19F: After 13vPnC dose Year 5 (n=125)17.37 (14.23 to 21.20)
Serotype 23F: Before 13vPnC dose Year 0 (n=80)0.97 (0.73 to 1.30)
Serotype 23F: After 13vPnC dose Year 0 (n=83)6.06 (4.38 to 8.39)
Serotype 23F: Year 1 (n=118)3.65 (2.96 to 4.51)
Serotype 23F: Year 2 (n=123)2.93 (2.40 to 3.57)
Serotype 23F: Year 3 (n=126)2.67 (2.19 to 3.25)
Serotype 23F: Year 4 (n=126)2.62 (2.16 to 3.17)
Serotype 23F: Before 13vPnC dose Year 5 (n=125)2.50 (2.05 to 3.04)
Serotype 23F: After 13vPnC dose Year 5 (n=125)16.95 (13.73 to 20.91)
Other pre-specifiedSerotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC (Year 0),1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5) Relative to Before 13vPnC (Year 0)

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined from before to 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5) and were summarized geometric means and 2-sided 95% CIs, which were computed using the logarithmically transformed assay results. CI for GMFRs were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rises. GMFRs were calculated using all participants with available data from both the baseline and the various time points.

Time frame:
Before, 1 month after 13vPnC (Year 0), at years 1, 2, 3 and 4 after initial vaccination (Year 0), before, 1 month after 13vPnC (Year 5)
Reported as:
Geometric mean · fold-rises
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) 1 Month After 13vPnC (Year 0),1, 2, 3, 4 Years After Initial Vaccination (Year 0); Before and 1 Month After 13vPnC (Year 5) Relative to Before 13vPnC (Year 0)
fold-risesAll Participants
Serotype 1:After 13vPnC dose at Year 0 (n=79)12.50 (9.25 to 16.90)
Serotype 1: Year 1 (n=72)5.64 (4.32 to 7.35)
Serotype 1: Year 2 (n=75)4.73 (3.73 to 6.00)
Serotype 1: Year 3 (n=76)4.01 (3.15 to 5.11)
Serotype 1: Year 4 (n=75)3.79 (3.00 to 4.78)
Serotype 1: Before 13vPnC dose Year 5 (n=76)3.41 (2.72 to 4.28)
Serotype 1: After 13vPnC dose at Year 5 (n=77)15.25 (11.63 to 19.99)
Serotype 3: After 13vPnC dose at Year 0 (n=80)2.69 (2.21 to 3.28)
Serotype 3: Year 1 (n=73)0.89 (0.74 to 1.07)
Serotype 3: Year 2 (n=77)0.77 (0.66 to 0.90)
Serotype 3: Year 3 (n= 77)0.72 (0.62 to 0.84)
Serotype 3: Year 4 (n=72)0.69 (0.58 to 0.82)
Serotype 3: Before 13vPnC dose Year 5 (n=74)0.65 (0.56 to 0.76)
Serotype 3: After 13vPnC dose at Year 5 (n=78)1.51 (1.22 to 1.87)
Serotype 4: After 13vPnC dose at Year 0 (n=79)12.81 (9.27 to 17.70)
Serotype 4: Year 1 (n=74)6.00 (4.52 to 7.96)
Serotype 4: Year 2 (n=75)4.63 (3.51 to 6.10)
Serotype 4: Year 3 (n=77)4.12 (3.11 to 5.46)
Serotype 4: Year 4 (n=76)3.82 (2.90 to 5.03)
Serotype 4: Before 13vPnC dose Year 5 (n=77)3.41 (2.61 to 4.46)
Serotype 4: After 13vPnC dose at Year 5 (n=78)24.99 (18.07 to 34.56)
Serotype 5: After 13vPnC dose at Year 0 (n=82)4.21 (3.27 to 5.43)
Serotype 5: Year 1 (n=75)2.43 (2.02 to 2.92)
Serotype 5: Year 2 (n=78)2.05 (1.74 to 2.42)
Serotype 5: Year 3 (n=79)1.86 (1.58 to 2.18)
Serotype 5: Year 4 (n=78)1.84 (1.58 to 2.16)
Serotype 5: Before 13vPnC dose Year 5 (n=79)1.74 (1.47 to 2.08)
Serotype 5: After 13vPnC dose at Year 5 (n=80)5.38 (4.26 to 6.80)
Serotype 6A: After 13vPnC dose Year 0 (n=82)4.32 (3.35 to 5.57)
Serotype 6A: Year 1 (n=75)2.66 (2.15 to 3.27)
Serotype 6A: Year 2 (n=78)2.15 (1.80 to 2.57)
Serotype 6A: Year 3 (n=79)1.96 (1.64 to 2.34)
Serotype 6A: Year 4 (n=78)1.91 (1.62 to 2.26)
Serotype 6A: Before 13vPnC dose Year 5 (n=79)1.74 (1.46 to 2.07)
Serotype 6A: After 13vPnC dose Year 5 (n=80)10.18 (7.50 to 13.82)
Serotype 6B: After 13vPnC dose Year 0 (n=81)5.50 (4.09 to 7.39)
Serotype 6B: Year 1 (n=74)3.24 (2.53 to 4.15)
Serotype 6B: Year 2 (n=77)2.59 (2.13 to 3.16)
Serotype 6B: Year 3 (n=78)2.36 (1.94 to 2.88)
Serotype 6B: Year 4 (n=77)2.20 (1.83 to 2.65)
Serotype 6B: Before 13vPnC dose Year 5 (n=78)1.92 (1.57 to 2.36)
Serotype 6B: After 13vPnC dose Year 5 (n=79)12.82 (9.51 to 17.26)
Serotype 7F: After 13vPnC dose Year 0 (n=81)14.60 (10.96 to 19.46)
Serotype 7F: Year 1 (n=75)6.28 (4.91 to 8.03)
Serotype 7F: Year 2 (n=77)5.03 (3.97 to 6.39)
Serotype 7F: Year 3 (n=78)4.12 (3.30 to 5.15)
Serotype 7F: Year 4 (n=77)3.87 (3.11 to 4.80)
Serotype 7F: Before 13vPnC dose Year 5 (n=77)3.63 (2.92 to 4.50)
Serotype 7F: After 13vPnC dose Year 5 (n=79)11.65 (8.85 to 15.33)
Serotype 9V: After 13vPnC dose Year 0 (n=80)5.81 (4.68 to 7.22)
Serotype 9V: Year 1 (n=75)3.34 (2.80 to 3.98)
Serotype 9V: Year 2 (n=77)2.90 (2.44 to 3.45)
Serotype 9V: Year 3 (n=77)2.60 (2.20 to 3.09)
Serotype 9V: Year 4 (n=76)2.51 (2.14 to 2.94)
Serotype 9V: Before 13vPnC dose Year 5 (n=77)2.24 (1.89 to 2.65)
Serotype 9V: After 13vPnC dose Year 5 (n=78)7.35 (5.92 to 9.12)
Serotype 14: After 13vPnC dose Year 0 (n=82)6.47 (4.43 to 9.46)
Serotype 14: Year 1 (n=75)4.00 (2.86 to 5.59)
Serotype 14: Year 2 (n=78)3.54 (2.61 to 4.82)
Serotype 14: Year 3 (n=79)3.10 (2.28 to 4.22)
Serotype 14: Year 4 (n=78)2.84 (2.10 to 3.83)
Serotype 14: Before 13vPnC dose Year 5 (n=79)2.68 (1.96 to 3.67)
Serotype 14: After 13vPnC dose Year 5 (n=80)6.94 (5.11 to 9.42)
Serotype 18C: After 13vPnC dose Year 0 (n=82)9.86 (7.35 to 13.23)
Serotype 18C: Year 1 (n=75)4.56 (3.54 to 5.87)
Serotype 18C: Year 2 (n=78)3.74 (2.95 to 4.74)
Serotype 18C: Year 3 (n=79)3.11 (2.42 to 4.01)
Serotype 18C: Year 4 (n=78)2.97 (2.38 to 3.71)
Serotype 18C: Before 13vPnC dose Year 5 (n=79)2.77 (2.21 to 3.46)
Serotype 18C: After 13vPnC dose Year 5 (n=80)8.73 (6.64 to 11.48)
Serotype 19A: After 13vPnC dose Year 0 (n=82)5.52 (4.44 to 6.87)
Serotype 19A: Year 1 (n=75)2.69 (2.21 to 3.28)
Serotype 19A: Year 2 (n=78)2.39 (2.00 to 2.85)
Serotype 19A: Year 3 (n=79)2.14 (1.80 to 2.54)
Serotype 19A: Year 4 (n=78)2.06 (1.75 to 2.42)
Serotype 19A: Before 13vPnC dose Year 5 (n=79)1.87 (1.59 to 2.21)
Serotype 19A: After 13vPnC dose Year 5 (n=80)6.00 (4.78 to 7.52)
Serotype 19F: After 13vPnC dose Year 0 (n=78)6.02 (4.68 to 7.75)
Serotype 19F: Year 1 (n=71)3.39 (2.66 to 4.32)
Serotype 19F: Year 2 (n=72)2.74 (2.22 to 3.39)
Serotype 19F: Year 3 (n=76)2.42 (1.97 to 2.98)
Serotype 19F: Year 4 (n=75)2.24 (1.85 to 2.72)
Serotype 19F: Before 13vPnC dose Year 5 (n=74)2.01 (1.59 to 2.55)
Serotype 19F: After 13vPnC dose Year 5 (n=76)18.16 (13.04 to 25.30)
Serotype 23F: After 13vPnC dose Year 0 (n=80)6.65 (5.03 to 8.78)
Serotype 23F: Year 1 (n=73)3.57 (2.90 to 4.40)
Serotype 23F: Year 2 (n=75)3.09 (2.53 to 3.78)
Serotype 23F: Year 3 (n=77)2.93 (2.35 to 3.65)
Serotype 23F: Year 4 (n=76)2.77 (2.23 to 3.46)
Serotype 23F: Before 13vPnC dose Year 5 (n=77)2.48 (2.01 to 3.07)
Serotype 23F: After 13vPnC dose Year 5 (n=78)16.52 (12.29 to 22.22)
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Dose 1 (Year 0)

Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder). Local reactions were measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.

Time frame:
Within 14 days after Dose 1 (Year 0)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Dose 1 (Year 0)
percentage of participants13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Redness: Any (n=282,263)16.33.0
Redness: Mild (n=281,262)15.72.7
Redness: Moderate (n=265,258)4.20.4
Redness: Severe (n=262,257)0.40.0
Swelling: Any (n=288,263)18.43.0
Swelling: Mild (n=288,263)17.03.0
Swelling: Moderate (n=263,257)5.70.0
Swelling: Severe (262,257)0.40.0
Pain: Any (n=469,321)86.837.1
Pain: Mild (n=459, 318)82.835.2
Pain: Moderate (n=324,261)39.24.2
Pain: Severe (n=267,258)4.10.4
Limitation of arm movement:Any(317,270)35.68.9
Limitation of arm movement:Mild(n=310,268)32.68.2
Limitation of arm movement: Moderate(n=269,259)5.21.2
Limitation of arm movement:Severe(n=266,258)3.40.8
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Dose 2 (Year 0)

Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder). Local reactions were measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.

Time frame:
Within 14 days after Dose 2 (Year 0)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Dose 2 (Year 0)
percentage of participants13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Redness: Any (n=238,257)1.712.1
Redness: Mild (n=238,255)1.710.2
Redness: Moderate (n=236,248)0.05.6
Redness: Severe (n=236,242)0.01.2
Swelling: Any (n=242,265)4.514.7
Swelling: Mild (n=242,260)4.512.3
Swelling: Moderate (n=236,249)0.46.4
Swelling: Severe (236,241)0.00.4
Pain: Any (n=294,453)32.084.5
Pain: Mild (n=290, 431)30.782.1
Pain: Moderate (n=243,319)4.541.1
Pain: Severe (n=236,248)0.04.8
Limitation of arm movement:Any(248,318)9.342.5
Limitation of arm movement:Mild(n=248,316)9.341.1
Limitation of arm movement: Moderate(n=236,248)0.45.2
Limitation of arm movement:Severe(n=236,244)0.02.9
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After 13vPnC (Year 5)

Specific local reactions were prompted for each day,and reported using an electronic diary.Redness and Swelling were scaled as Any(redness present or swelling present);Mild(2.5 to 5.0 centimeters \[cm\]);Moderate(5.1 to 10.0 cm);Severe (\>10 cm). Pain at injection site was scaled as: Any (pain present); Mild (awareness of sign or symptom, but easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, with inability to do usual activity). Limitation of arm movement was scaled as Any(no limitation of arm movement);Mild(some limitation of arm movement);Moderate (unable to move arm above head but able to move arm above shoulder);Severe (unable to move arm above shoulder).

Time frame:
Within 14 days after 13vPnC (Year 5)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After 13vPnC (Year 5)
percentage of participants13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Redness: Any (n=216,215)15.720.9
Redness: Mild (n=215,212)14.017.5
Redness: Moderate (n=210,211)7.112.3
Redness: Severe (n=205,202)1.50.5
Swelling: Any (n=224,216)18.818.1
Swelling: Mild (n=223,214)17.515.9
Swelling: Moderate (n=211,208)7.19.6
Swelling: Severe (205,203)0.01.0
Pain: Any (n=313,306)79.279.4
Pain: Mild (n=297, 299)76.474.9
Pain: Moderate (n=248,235)32.734.9
Pain: Severe (n=206,205)4.43.4
Limitation of arm movement:Any(233,224)23.226.3
Limitation of arm movement:Mild(n=233,219)22.322.8
Limitation of arm movement: Moderate(n=208,206)2.93.9
Limitation of arm movement:Severe(n=206,206)1.93.4
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Dose 1 (Year 0)

Percentage of participants who experienced specific systemic events (mild: 38.0 to 38.4 degrees Celsius \[C\], moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening greater than \[\>\] 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.

Time frame:
Within 14 days after Dose 1 (Year 0)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Dose 1 (Year 0)
percentage of participants13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Fever: >=38 but <38.5 degree C(n=261,259)1.51.2
Fever: >=38.5 but <39 degree C(n=262,257)1.50.0
Fever: >=39 but =<40.0 degree C(n=261,257)0.40.0
Fever:>40.0 degree C (n=261,257)0.00.4
Fatigue(n=389,359)58.152.4
Headache(n=399,382)65.956.5
Chills(n=306,291)31.421.0
Rash(n=278,264)12.64.9
Vomiting(n=266,262)5.33.4
Decreased appetite(n=315,301)30.222.6
New generalized muscle pain(n=385,326)65.537.7
Aggravated generalized muscle pain(n=314,294)34.724.1
New generalized joint pain(n=309,296)33.024.7
Aggravated generalized joint pain(n=292,284)21.218.0
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Dose 2 (Year 0)

Percentage of participants who experienced specific systemic events (absent: 38.0 degrees Celsius \[C\], mild: 38.0 to 38.4 degrees C, moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening \> 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.

Time frame:
Within 14 days after Dose 2 (Year 0)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Dose 2 (Year 0)
percentage of participants13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Fever: >=38 but <38.5 degree C(n=238,241)1.31.2
Fever: >=38.5 but <39 degree C(n=239,240)1.30.8
Fever: >=39 but =<40 degree (n=236,240)0.40.4
Fever: >40.0 degree C(n=237,240)0.40.0
Fatigue (n=316,338)43.751.8
Headache (n=334,338)48.250.9
Chills (n=273,276)20.524.6
Rash (n=246,252)6.19.5
Vomiting (n=247,247)6.96.1
Decreased appetite(n=270,279)20.425.8
New generalized muscle pain(n=288,350)28.559.1
Aggravated generalized muscle pain(n=268,305)18.736.7
New generalized joint pain(n=268,285)20.527.4
Aggravated generalized joint pain(n=264,282)15.523.8
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After 13vPnC (Year 5)

Percentage of participants who experienced specific systemic events (Fever: \>= 38.0 degrees Celsius \[C\], mild: 38.0 to 38.4 degrees C, moderate: 38.5 to 38.9 degrees C, severe: 39.0 to 40.0 degrees C and potentially life threatening \> 40.0 degrees C), chills, fatigue, headache, vomiting, decreased appetite, rash, new generalized muscle pain, aggravated generalized muscle pain, new generalized joint pain, and aggravated generalized joint pain prompted for each day were reported using an electronic diary.

Time frame:
Within 14 days after 13vPnC (Year 5)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After 13vPnC (Year 5)
percentage of participants13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Fever: >= 38.0 degrees C (n=206,209)2.45.3
Fever: >=38 but <38.5 degree C(n=205,206)1.02.4
Fever: >=38.5 but <39 degree C(n=206,204)0.52.0
Fever: >=39 but =<40 degree C(n=205,202)0.00.0
Fever: >40 degree C(n=205,204)1.01.5
Fatigue(n=263,251)43.745.8
Headache(n=256,248)46.951.2
Chills(n=229,217)23.122.1
Rash(n=209,210)7.713.8
Vomiting(n=206,207)3.47.2
Decreased appetite(n=226,227)20.422.0
New generalized muscle pain(n=266,253)47.751.0
Aggravated generalized muscle pain(n=241,223)29.927.4
New generalized joint pain(n=219,219)19.221.9
Aggravated generalized joint pain(n=218,214)17.418.2
Other pre-specifiedPercentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After Dose 1 (Year 0)

Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity). Acute pain was measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.

Time frame:
Within 30 Minutes After Dose 1 (Year 0)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After Dose 1 (Year 0)
percentage of participants13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Acute pain (Dose 1):Mild6.76.3
Acute pain (Dose 1):Moderate0.00.0
Acute pain (Dose 1):Severe0.00.0
Acute pain (Dose 1): Any6.76.3
Other pre-specifiedPercentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After Dose 2 (Year 0)

Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity). Acute pain was measured only on the participant's arm vaccinated with either 13vPnC or placebo and were not collected at the TIV injection site.

Time frame:
Within 30 Minutes After Dose 2 (Year 0)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After Dose 2 (Year 0)
percentage of participants13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Acute pain (Dose 2):Mild5.96.4
Acute pain (Dose 2):Moderate0.00.0
Acute pain (Dose 2):Severe0.00.0
Acute pain (Dose 2):Any5.96.4
Other pre-specifiedPercentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After 13vPnC (Year 5)

Acute pain was not prompted in the electronic diary however were recorded in a specific page of the case report form (CRF). Acute pain at injection site pain occurred within 30 minutes of vaccination and was scaled as: Any (pain present); Mild (easily tolerated); Moderate (discomfort interfering the usual activity); Severe (Incapacitating with inability to do usual activity).

Time frame:
Within 30 Minutes After 13vPnC (Year 5)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Acute Pain Within 30 Minutes After 13vPnC (Year 5)
percentage of participants13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
Acute pain at injection site:Mild3.84.4
Acute pain at injection site:Moderate0.30.0
Acute pain at injection site:Severe0.00.0
Acute pain at injection site: Any4.14.4
Other pre-specifiedPercentage of Participants With Serious Adverse Events (SAEs) or Non-serious Adverse Events (Non-SAEs)

AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Non-serious AEs are AEs excluding SAEs. In Years 1-4, only deaths and withdrawals due to AEs or SAEs were to be recorded in the case report form.

Time frame:
Signing of informed consent up to 194 days after re-vaccination at Year 5
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) or Non-serious Adverse Events (Non-SAEs)
percentage of participants13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)
SAEs at Dose 1 (Year 0) (n=551,560)0.70.9
SAEs at Dose 2 (Year 0) (n=538,543)0.61.1
SAEs at 6-month follow-up (Year 0) (n=538,543)3.31.8
SAEs at Years 1-4(n=536,542)1.50.6
SAEs at 13vPnC (Year 5)(n=364,363)0.50.6
SAEs at 6-month follow-up (Year 5)(n=364,363)0.50.5
non-SAEs at Dose 1 (Year 0)(n=551,560)0.50.8
non-SAEs at Dose 2 (Year 0)(n=538,543)16.213.2
non-SAEs at 6-month follow-up (Year 0)(n=538,543)11.310.9
non-SAEs at Years 1-4(n=536,542)0.20.0
non-SAEs at 13vPnC (Year 5)(n=364,363)4.73.6
non-SAEs at 6-month follow-up (Year 5)(n=364,363)0.368.3

Adverse events

Collected over AEs/SAEs recorded: All AEs for 1 month postvaccination. All SAEs and newly diagnosed chronic medical conditions for 6 months postvaccination. Deaths and withdrawals due to S/AE in Years 1-4. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC+TIV/Placebo: Dose 1 (Year 0)—4/551 (0.7%)420/551 (76.2%)
13vPnC+TIV/Placebo: Dose 2 (Year 0)—3/538 (0.6%)248/538 (46.1%)
13vPnC+TIV/Placebo: 6 Month Follow-up (Year 0)—18/538 (3.3%)26/538 (4.8%)
13vPnC+TIV/Placebo: Years 1-4—8/536 (1.5%)1/536 (0.2%)
13vPnC+TIV/Placebo: 13vPnC (Year 5)—2/364 (0.5%)256/364 (70.3%)
13vPnC+TIV/Placebo: 6 Month Follow-up (Year 5)—2/364 (0.5%)1/364 (0.3%)
Placebo+TIV/13vPnC: Dose 1 (Year 0)—5/560 (0.9%)326/560 (58.2%)
Placebo+TIV/13vPnC: Dose 2 (Year 0)—6/543 (1.1%)388/543 (71.5%)
Placebo+TIV/13vPnC: 6 Month Follow-up (Year 0)—10/543 (1.8%)29/543 (5.3%)
Placebo+TIV/13vPnC: Years 1-4—3/542 (0.6%)0/542 (0%)
Placebo+TIV/13vPnC: 13vPnC (Year 5)—2/363 (0.6%)248/363 (68.3%)
Placebo+TIV/13vPnC: 6 Month Follow-up (Year 5)—3/363 (0.8%)0/363 (0%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
Event13vPnC+TIV/Placebo: Dose 1 (Year 0)13vPnC+TIV/Placebo: Dose 2 (Year 0)13vPnC+TIV/Placebo: 6 Month Follow-up (Year 0)13vPnC+TIV/Placebo: Years 1-413vPnC+TIV/Placebo: 13vPnC (Year 5)13vPnC+TIV/Placebo: 6 Month Follow-up (Year 5)Placebo+TIV/13vPnC: Dose 1 (Year 0)Placebo+TIV/13vPnC: Dose 2 (Year 0)Placebo+TIV/13vPnC: 6 Month Follow-up (Year 0)Placebo+TIV/13vPnC: Years 1-4Placebo+TIV/13vPnC: 13vPnC (Year 5)Placebo+TIV/13vPnC: 6 Month Follow-up (Year 5)
Myocardial infarctionCardiac disorders0/5510/5381/5382/5360/3640/3641/5600/5430/5430/5420/3630/363
DiverticulitisInfections and infestations0/5510/5382/5380/5360/3640/3640/5600/5431/5430/5420/3630/363
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5510/5382/5380/5360/3640/3640/5600/5430/5430/5420/3631/363
Renal colicRenal and urinary disorders0/5510/5380/5380/5360/3640/3640/5600/5430/5430/5420/3631/363
ThrombosisVascular disorders1/5510/5380/5380/5360/3640/3640/5600/5430/5430/5421/3630/363
OsteoarthritisMusculoskeletal and connective tissue disorders0/5510/5381/5380/5360/3640/3640/5601/5430/5430/5420/3631/363
Clostridium difficile infectionInfections and infestations0/5510/5380/5380/5360/3640/3640/5600/5430/5430/5421/3630/363
Uterine prolapseReproductive system and breast disorders0/5510/5380/5380/5361/3640/3640/5600/5430/5430/5420/3630/363
ArthritisMusculoskeletal and connective tissue disorders0/5510/5380/5380/5360/3641/3640/5600/5430/5430/5420/3630/363
Spinal column stenosisMusculoskeletal and connective tissue disorders0/5510/5380/5380/5361/3640/3640/5601/5430/5430/5420/3630/363
Most frequent other events
Showing 10 of 217
Most frequent other events
Event13vPnC+TIV/Placebo: Dose 1 (Year 0)13vPnC+TIV/Placebo: Dose 2 (Year 0)13vPnC+TIV/Placebo: 6 Month Follow-up (Year 0)13vPnC+TIV/Placebo: Years 1-413vPnC+TIV/Placebo: 13vPnC (Year 5)13vPnC+TIV/Placebo: 6 Month Follow-up (Year 5)Placebo+TIV/13vPnC: Dose 1 (Year 0)Placebo+TIV/13vPnC: Dose 2 (Year 0)Placebo+TIV/13vPnC: 6 Month Follow-up (Year 0)Placebo+TIV/13vPnC: Years 1-4Placebo+TIV/13vPnC: 13vPnC (Year 5)Placebo+TIV/13vPnC: 6 Month Follow-up (Year 5)
Any local reactionSkin and subcutaneous tissue disorders420/474105/3000/5380/536256/3150/364128/325388/4560/5430/542248/3080/363
Pain: AnySkin and subcutaneous tissue disorders407/46994/2940/5380/536248/3130/364119/321383/4530/5430/542243/3060/363
Any systemic eventGeneral disorders417/484248/3810/5380/536221/3070/364326/430326/4250/5430/542218/2900/363
Pain: MildSkin and subcutaneous tissue disorders380/45989/2900/5380/536227/2970/364112/318354/4310/5430/542224/2990/363
Headache: anyGeneral disorders263/399161/3340/5380/536120/2560/364216/382172/3380/5430/542127/2480/363
New muscle pain: anyGeneral disorders252/38582/2880/5380/536127/2660/364123/326207/3500/5430/542129/2530/363
Fatigue: anyGeneral disorders226/389138/3160/5380/536115/2630/364188/359175/3380/5430/542115/2510/363
Limitation of arm movement: AnySkin and subcutaneous tissue disorders113/31723/2480/5380/53654/2330/36424/270135/3180/5430/54259/2240/363
Limitation of arm movement: MildSkin and subcutaneous tissue disorders101/31023/2480/5380/53652/2330/36422/268130/3160/5430/54250/2190/363
Pain: ModerateSkin and subcutaneous tissue disorders127/32411/2430/5380/53681/2480/36411/261131/3190/5430/54282/2350/363

Baseline characteristics

Safety analysis set included all randomized participants who had received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)Total
Mean54.6 ± 2.854.6 ± 2.954.6 ± 2.8
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC+TIV/Placebo (Year 0) and 13vPnC (Year 5)Placebo+TIV/13vPnC (Year 0) and 13vPnC (Year 5)Total
Female319322641
Male232238470
08

Study locations

41 sites
  • Clinical Research Advantage, Inc.
    Chandler, Arizona 85224, United States
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
  • Clinical Trials Center Pediatric Infectious Diseases and Clinical Trials
    Aurora, Colorado 80045-7144, United States
  • Tampa Bay Medical Research, Inc.
    Clearwater, Florida 33761, United States
  • A. G. A. Clinical Trials
    Hialeah, Florida 33012, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Accelovance
    Peoria, Illinois 61602, United States
  • Suite 100
    Riverdale, Maryland 20737, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Radiant Research, Inc
    St. Louis, Missouri 63141, United States
  • Big Sky Clinical Research
    Butte, Montana 59701, United States
  • FFM Clinical Research
    Camillus, New York 13031, United States
  • Rochester Clinical Research
    Rochester, New York 14609, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • PMG Research of Raleigh, LLC
    Cary, North Carolina 27518, United States
  • Hickory Family Practice Associates
    Hickory, North Carolina 28601, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28601, United States
  • Unifour Medical Research Associates, LLC
    Hickory, North Carolina 28601, United States
  • Unifour Medical Research Associates
    Hickory, North Carolina 28601, United States
  • Fairbrook Medical Clinic
    Hickory, North Carolina 28602, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28602, United States
  • Unifour Medical Research Associates, LLC
    Hickory, North Carolina 28602, United States
  • PMG Research of Raleigh, LLC
    Raleigh, North Carolina 27609, United States
  • PMG Research of Salisbury
    Salisbury, North Carolina 28144, United States
  • PMG Research of Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Cincinnati Children's Hospital Medical Center Gamble Program for Clinical Studies
    Cincinnati, Ohio 45206, United States
  • Rapid Medical Research, Inc.
    Cleveland, Ohio 44122, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Preferred Primary Care Physicians, Inc
    Carnegie, Pennsylvania 15106, United States
  • Family Healthcare Partners
    Grove City, Pennsylvania 16127, United States
  • Family Practice Medical Associates South, Jefferson Office
    Jefferson Hills, Pennsylvania 15025, United States
  • Kid's Plus Pediatrics
    Pittsburgh, Pennsylvania 15217, United States
  • Primary Physicians Research Inc.
    Pittsburgh, Pennsylvania 15241, United States
  • Family Practice Medical Associates South
    Upper St. Clair, Pennsylvania 15241, United States
  • The Washington Hospital Family Medicine
    Washington, Pennsylvania 15301, United States
  • Internal Medicine & Pediatric Associates of Bristol, PC
    Bristol, Tennessee 37620, United States
  • PMG Research of Bristol, LLC
    Bristol, Tennessee 37620, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Clark D. McKeever, M.D. Research for Health
    Houston, Texas 77055-6040, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
09

References and documents

Publications

  • Frenck RW Jr, Fiquet A, Gurtman A, van Cleeff M, Davis M, Rubino J, Smith W, Sundaraiyer V, Sidhu M, Emini EA, Gruber WC, Scott DA, Schmoele-Thoma B; B1851020 Study Group. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine. 2016 Jun 24;34(30):3454-62. doi: 10.1016/j.vaccine.2016.04.093. Epub 2016 May 5. PubMed 27155493 ↗
  • Frenck RW Jr, Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D, Giardina PC, Emini EA, Gruber WC, Scott DA, Schmole-Thoma B. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012 Aug;19(8):1296-303. doi: 10.1128/CVI.00176-12. Epub 2012 Jun 27. PubMed 22739693 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2007
First posted
Aug 28, 2007
Start
Sep 2007
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Apr 9, 2015
Last update
Apr 9, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00521586
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 28, 2007
Start date
Sep 2007
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Apr 9, 2015
Last update
Apr 9, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion